Skip to NavigationSkip to content

Pharmafile - Research and Development News

Gilead has presented new Phase 1b data on the combination of magrolimab with azacitidine, showing positive responses in treatment-naïve...
The UK-based Drug Safety Research Unit (DSRU) has reported its findings from the first ever systematic benefit-risk analysis of Gilead’s remdesivir,...
MSD has pulled back the curtain on new data from two trials of its anti-PD-1 immunotherapy Keytruda (pemvbrolizmuab) in combination with Eisai’s...
The FDA has approved Sanofi’s Dupixent (dupilumab) for children between ages 6 to 11 with moderate to severe atopic dermatitis.
The Pharmafocus June issue is available online now, featuring an in-depth look at the impact of COVID-19 on the rare disease community, and how data...
COVID-19 vaccines and treatments continue to dominate the news, as AstraZeneca is attempting to deliver one billion doses of coronavirus vaccine by...
NHS patients with treatment-naïve extensive-stage small-cell lung cancer (ES-SCLC) in England and Wales will soon have access to a new treatment...
Gilead Sciences Ebola drug remdesivir will be available for selected patients who are suffering from coronavirus through the NHS.
The findings provide hope for the idea that the immune system could potentially provide immunity to COVID-19 reinfection, buoying hopes that an...
More becomes known about the virus as NHS data revealed that 26% of all English COVID-19 deaths were in diabetics, while the one of the most...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches